Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) levels and cardiovascular ...

Comparing extremes of the spectrum, multivariable analyses generally showed significantly higher risks for patients with high ...

A new study published in the Journal of American Medical Association showed that among healthy women, very high lipoprotein ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Lipoprotein(a), a fatty particle, can clog arteries just as surely as cholesterol but often goes undetected, striking seemingly healthy people unaware of the danger.

Every Australian adult should be screened for a potentially deadly type of inherited cholesterol, and if the simple blood ...

When considering the risk factors for heart disease, some conditions may come readily to mind: obesity, unhealthy diet, and high cholesterol. People who have a parent or close relative with heart ...

All sex, race, and risk category groups appeared to be affected by the heart disease risk posed by elevated lipoprotein(a), or Lp(a), according to pooled analysis of primary prevention studies.